$ESPR
Esperion Therapeutics Inc Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000162828024046307 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$51.63M
YoY Change		52.0%
Cost Of Revenue		$17.29M
YoY Change		29.0%
Gross Profit		$34.35M
YoY Change		66.73%
Gross Profit Margin		66.52%
Selling, General & Admin		$39.98M
YoY Change		20.26%
% of Gross Profit		116.39%
Research & Development		$10.40M
YoY Change		-30.15%
% of Gross Profit		30.27%
Depreciation & Amortization		$26.00K
YoY Change		-13.33%
% of Gross Profit		0.08%
Operating Expenses		$67.66M
YoY Change		10.01%
Operating Profit		-$16.03M
YoY Change		-41.79%
Interest Expense		-$15.08M
YoY Change		-200.58%
% of Operating Profit
Other Income/Expense, Net		$1.584M
YoY Change		23.94%
Pretax Income		-$29.52M
YoY Change		-28.51%
Income Tax		$0.00
% Of Pretax Income
Net Earnings		-$29.52M
YoY Change		-28.43%
Net Earnings / Revenue		-57.18%
Basic Earnings Per Share		-$0.15
Diluted Earnings Per Share		-$0.15
COMMON SHARES
Basic Shares Outstanding	197.0M shares	196.2M shares
Diluted Shares Outstanding		194.9M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$144.7M
YoY Change		26.06%
Cash & Equivalents		$144.7M
Short-Term Investments
Other Short-Term Assets		$14.91M
YoY Change		60.34%
Inventory		$80.10M
Prepaid Expenses
Receivables		$67.82M
Other Receivables		$0.00
Total Short-Term Assets		$307.6M
YoY Change		40.93%
LONG-TERM ASSETS
Property, Plant & Equipment		$281.0K
YoY Change		4583.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets		$6.559M
YoY Change		113.09%
TOTAL ASSETS
Total Short-Term Assets		$307.6M
Total Long-Term Assets		$6.559M
Total Assets		$314.1M
YoY Change		41.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$34.86M
YoY Change		33.0%
Accrued Expenses		$77.54M
YoY Change		41.49%
Deferred Revenue		$15.08M
YoY Change		-23.55%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$165.9M
YoY Change		20.45%
LONG-TERM LIABILITIES
Long-Term Debt		$262.9M
YoY Change		0.66%
Other Long-Term Liabilities		$255.5M
YoY Change		9.95%
Total Long-Term Liabilities		$518.5M
YoY Change		5.03%
TOTAL LIABILITIES
Total Short-Term Liabilities		$165.9M
Total Long-Term Liabilities		$518.5M
Total Liabilities		$684.3M
YoY Change		8.4%
SHAREHOLDERS EQUITY
Retained Earnings		-$1.580B
YoY Change		5.81%
Common Stock		$195.0K
YoY Change		74.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$370.2M
YoY Change
Total Liabilities & Shareholders Equity		$314.1M
YoY Change		41.94%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$29.52M
YoY Change		-28.43%
Depreciation, Depletion And Amortization		$26.00K
YoY Change		-13.33%
Cash From Operating Activities		-$35.32M
YoY Change		82.84%
INVESTING ACTIVITIES
Capital Expenditures		$167.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		-$167.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-9.095M
YoY Change		111.02%
NET CHANGE
Cash From Operating Activities		-35.32M
Cash From Investing Activities		-167.0K
Cash From Financing Activities		-9.095M
Net Change In Cash		-44.59M
YoY Change		88.69%
FREE CASH FLOW
Cash From Operating Activities		-$35.32M
Capital Expenditures		$167.0K
Free Cash Flow		-$35.49M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
	dei	City Area Code CityAreaCode	734
	dei	Local Phone Number LocalPhoneNumber	887-3903
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ESPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	197035171	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	144717000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82248000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	15078000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25402000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2741000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1553000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	165873000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	156224000	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	262922000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	261596000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1579711000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1549284000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-370209000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-454994000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	314114000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205796000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51632000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33969000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	84084000	usd
	us-gaap	Operating Expenses OperatingExpenses	204379000	usd
	us-gaap	Operating Expenses OperatingExpenses	197280000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16026000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-27533000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	58822000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-113196000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	194930830	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194930830	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111869478	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
CY2024Q3	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	0	usd
CY2023Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	239950000	usd
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	263201000	usd
CY2024Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	17286000	usd
CY2023Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	13377000	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	42970000	usd
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	31815000	usd
CY2024Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10397000	usd
CY2023Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14885000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35261000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	68365000	usd
CY2024Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39975000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	33240000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	126148000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	67658000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97100000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	61502000	usd
	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	48494000	usd
CY2024Q3	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	499000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	201065000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	281000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6222000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4675000	usd
CY2024Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	usd
CY2024Q3	us-gaap	Assets Assets	314114000	usd
CY2023Q4	us-gaap	Assets Assets	205796000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	34864000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31718000	usd
CY2024Q3	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	3546000	usd
CY2023Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	3441000	usd
CY2024Q3	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	52003000	usd
CY2023Q4	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	34284000	usd
CY2024Q3	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	19247000	usd
CY2023Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24998000	usd
CY2024Q3	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	0	usd
CY2023Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	34828000	usd
	dei	Entity File Number EntityFileNumber	001-35986
	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67824000	usd
CY2023Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	193000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	80102000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65623000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14413000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4507000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	307555000	usd
CY2024Q3	espr	Royalty Sale Liability Current RoyaltySaleLiabilityCurrent	38394000	usd
CY2023Q4	espr	Royalty Sale Liability Current RoyaltySaleLiabilityCurrent	0	usd
CY2024Q3	espr	Royalty Sale Liability Non Current RoyaltySaleLiabilityNonCurrent	252229000	usd
CY2023Q4	espr	Royalty Sale Liability Non Current RoyaltySaleLiabilityNonCurrent	0	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3299000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3020000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	684323000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	660790000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	480000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	480000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	197434696	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	195000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1264305000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1149170000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1994198	shares
CY2024Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1994198	shares
CY2024Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	54998000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	42829000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	43919000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53235000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6815000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4211000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30427000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152904000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.53
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	111869478	shares
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30427000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-152902000	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	120204513	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	118000	usd
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	54998000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	15082000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	14995000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1584000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1278000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-29524000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-41250000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	184366434	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	184366434	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	99973647	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99973647	shares
CY2024Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29524000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-41250000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-323778000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	502000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2903000	usd
CY2023Q1	espr	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	52428000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-61719000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-329663000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3160000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4448000	usd
CY2023Q2	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	10000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-49935000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-371978000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	238000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2975000	usd
CY2023Q3	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	11000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-41250000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-410004000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-454994000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3235000	usd
CY2024Q1	espr	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	90672000	usd
CY2024Q1	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	5766000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	61022000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-294298000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2931000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29000	usd
CY2024Q2	espr	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	9042000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-61925000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-344220000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3022000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	513000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-29524000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-370209000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-30427000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-152904000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53235000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	espr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	16391000	usd
	espr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	usd
	us-gaap	Depreciation Depreciation	36000	usd
	us-gaap	Depreciation Depreciation	158000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	412000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1326000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1266000	usd
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	21569000	usd
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	34703000	usd
	espr	Non Cash Interest Expense Related To Royalty Sale Liability NonCashInterestExpenseRelatedToRoyaltySaleLiability	11984000	usd
	espr	Non Cash Interest Expense Related To Royalty Sale Liability NonCashInterestExpenseRelatedToRoyaltySaleLiability	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9188000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9038000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	19330000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8894000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10212000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1556000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10324000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	16216000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	14479000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	16234000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3128000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3174000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	11995000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	13902000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11298000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-98431000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	42500000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	317000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-317000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	42500000	usd
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	5832000	usd
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	10908000	usd
	espr	Payments For Repurchase Of Revenue Interest Liability PaymentsForRepurchaseOfRevenueInterestLiability	343750000	usd
	espr	Payments For Repurchase Of Revenue Interest Liability PaymentsForRepurchaseOfRevenueInterestLiability	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9626000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	espr	Proceeds From Royalty Sale Liability Net Of Issuance Costs ProceedsFromRoyaltySaleLiabilityNetOfIssuanceCosts	304656000	usd
	espr	Proceeds From Royalty Sale Liability Net Of Issuance Costs ProceedsFromRoyaltySaleLiabilityNetOfIssuanceCosts	0	usd
	espr	Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts	0	usd
	espr	Proceeds From Issuance Of Common Stock Warrants And Pre Funded Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockWarrantsAndPreFundedWarrantsNetOfIssuanceCosts	52428000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	90672000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	espr	Proceeds From Issuance Of Common Stock From Atm Program ProceedsFromIssuanceOfCommonStockFromATMProgram	531000	usd
	espr	Proceeds From Issuance Of Common Stock From Atm Program ProceedsFromIssuanceOfCommonStockFromATMProgram	4448000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14808000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	espr	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	0	usd
	espr	Proceeds From Pre Funded Warrant Exercises ProceedsFromPreFundedWarrantExercises	21000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51488000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	45989000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	62469000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9942000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82248000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	124775000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	144717000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	114833000	usd
	espr	Common Stock Issuance Costs Incurred Not Yet Paid CommonStockIssuanceCostsIncurredNotYetPaid	18000	usd
	espr	Common Stock Issuance Costs Incurred Not Yet Paid CommonStockIssuanceCostsIncurredNotYetPaid	0	usd
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	80000	usd
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	62000	usd
CY2019Q3	espr	Estimated Number Of Study Patients EstimatedNumberOfStudyPatients	14000	patient
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000.0	usd
CY2024Q1	espr	Settlement Agreement Time Required To Pay Cash Portion Of Settlement SettlementAgreementTimeRequiredToPayCashPortionOfSettlement	P15D
CY2024Q1	espr	Settlement Agreement Aggregate Second Milestone Payment From Partner SettlementAgreementAggregateSecondMilestonePaymentFromPartner	25000000.0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2024 and December 31, 2023, eleven customers accounted for all of the Company's net trade receivables. As of September 30, 2024 and December 31, 2023, three customers held approximately 98% and 96% of the Company's trade receivables associated with net product sales, respectively. For the nine months ended September 30, 2024 and 2023, three customers accounted for approximately 98% and 95% of gross sales of NEXLETOL and NEXLIZET, respectively.</span></div>
	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000.0	usd
CY2024Q1	espr	Settlement Agreement Time Required To Pay Cash Portion Of Settlement SettlementAgreementTimeRequiredToPayCashPortionOfSettlement	P15D
CY2024Q1	espr	Settlement Agreement Aggregate Second Milestone Payment From Partner SettlementAgreementAggregateSecondMilestonePaymentFromPartner	25000000.0	usd
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000	usd
CY2024Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	71379000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	61890000	usd
CY2024Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4695000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1728000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4028000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2005000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	80102000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	65623000	usd
CY2023Q2	espr	Potential Proceeds From Partner Milestone Payments PotentialProceedsFromPartnerMilestonePayments	300000000	usd
CY2024Q1	espr	Settlement Agreement Aggregate First Milestone Payment From Partner SettlementAgreementAggregateFirstMilestonePaymentFromPartner	100000000.0	usd
CY2024Q1	espr	Settlement Agreement Time Required To Pay Cash Portion Of Settlement SettlementAgreementTimeRequiredToPayCashPortionOfSettlement	P15D
CY2024Q1	espr	Settlement Agreement Aggregate Second Milestone Payment From Partner SettlementAgreementAggregateSecondMilestonePaymentFromPartner	25000000.0	usd
	espr	Abbreviated New Drug Application Litigation Number Of Notices Received AbbreviatedNewDrugApplicationLitigationNumberOfNoticesReceived	9	company
CY2024Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	106258000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	106258000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	68847000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	68847000	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	usd
	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2024Q3	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2023Q3	espr	Fair Value Measurement Asset Transfers Between Levels FairValueMeasurementAssetTransfersBetweenLevels	0	usd
CY2022Q4	espr	One Time Partial Call OneTimePartialCall	50000000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53200000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-53235000	usd
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	usd
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	usd
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	usd
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	usd
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	448698	shares
CY2024Q3	espr	Accrued Legal Fees Current AccruedLegalFeesCurrent	301000	usd
CY2023Q4	espr	Accrued Legal Fees Current AccruedLegalFeesCurrent	9202000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11139000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10769000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3375000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2712000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	3975000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1325000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	457000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	990000	usd
CY2024Q3	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	19247000	usd
CY2023Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24998000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3686191	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.88
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	584000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2082000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	588724	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.82
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1956	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.62
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5177511	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	52000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5177511	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M8D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	52000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2399531	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.14
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y2M15D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	49000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2900000	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26071429	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36344212	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44897299	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	85867716	shares
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-046307-index-headers.html	Edgar Link	pending
0001628280-24-046307-index.html	Edgar Link	pending
0001628280-24-046307.txt	Edgar Link	pending
0001628280-24-046307-xbrl.zip	Edgar Link	pending
espr-20240930.htm	Edgar Link	pending
espr-20240930.xsd	Edgar Link	pending
espr-ex311x09302024.htm	Edgar Link	pending
espr-ex312x09302024.htm	Edgar Link	pending
espr-ex321x09302024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
espr-20240930_def.xml	Edgar Link	unprocessable
espr-20240930_lab.xml	Edgar Link	unprocessable
espr-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
espr-20240930_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
espr-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics Inc Stock $espr

2024 Q4 Form 10-Q Financial Statement

#000162828024046307 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics Inc Stock $espr

2024 Q4 Form 10-Q Financial Statement

#000162828024046307 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics Inc Stock $espr